CINECA IRIS Institutional Research Information System

MASSAIA, Massimo Giovanni Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.439
EU - Europa 7.525
AS - Asia 4.300
AF - Africa 167
SA - Sud America 78
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 29
Totale 22.589
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.254
CN - Cina 2.305
IT - Italia 1.135
DE - Germania 1.123
SE - Svezia 1.004
SG - Singapore 974
IE - Irlanda 877
UA - Ucraina 771
FR - Francia 644
FI - Finlandia 496
AT - Austria 436
KR - Corea 368
GB - Regno Unito 321
PL - Polonia 228
IN - India 173
VN - Vietnam 161
CA - Canada 155
SN - Senegal 112
NL - Olanda 73
GR - Grecia 66
JP - Giappone 65
RU - Federazione Russa 60
DK - Danimarca 58
ID - Indonesia 56
AU - Australia 47
BE - Belgio 47
HK - Hong Kong 44
BR - Brasile 34
ES - Italia 32
TR - Turchia 29
EU - Europa 26
BY - Bielorussia 25
CH - Svizzera 24
MX - Messico 24
UZ - Uzbekistan 22
TW - Taiwan 21
PT - Portogallo 20
CL - Cile 16
ZA - Sudafrica 16
HU - Ungheria 14
IR - Iran 13
NO - Norvegia 13
TH - Thailandia 13
AR - Argentina 12
MU - Mauritius 12
RO - Romania 12
SA - Arabia Saudita 12
CZ - Repubblica Ceca 10
EG - Egitto 10
CO - Colombia 9
RS - Serbia 9
IL - Israele 8
MK - Macedonia 8
LU - Lussemburgo 6
MA - Marocco 6
PK - Pakistan 6
PE - Perù 5
BD - Bangladesh 4
DZ - Algeria 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
HR - Croazia 3
KZ - Kazakistan 3
LT - Lituania 3
PH - Filippine 3
AP - ???statistics.table.value.countryCode.AP??? 2
CU - Cuba 2
HN - Honduras 2
IQ - Iraq 2
LV - Lettonia 2
NG - Nigeria 2
SI - Slovenia 2
TG - Togo 2
A1 - Anonimo 1
BG - Bulgaria 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
GI - Gibilterra 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
UY - Uruguay 1
YE - Yemen 1
ZW - Zimbabwe 1
Totale 22.589
Salva come PNG Salva come JPEG
Città #
Beijing 1.702
Chandler 1.226
Dublin 874
Santa Clara 774
Singapore 746
Jacksonville 521
Ashburn 497
Houston 449
Vienna 433
Ann Arbor 410
Villeurbanne 355
Medford 322
Nyköping 318
Fairfield 298
Dearborn 290
Princeton 281
Wilmington 264
Columbus 244
Torino 226
Warsaw 215
Woodbridge 191
San Mateo 182
Seattle 138
Milan 133
Redwood City 125
Fremont 117
Turin 112
Cambridge 106
Pisa 96
Dong Ket 93
Munich 85
Boston 82
Boardman 80
Toronto 75
New York 67
Washington 66
Shanghai 62
Guangzhou 58
Jakarta 53
Rome 46
Nanjing 45
Düsseldorf 44
Helsinki 43
Pune 43
Hefei 42
Norwalk 40
Falls Church 36
Verona 36
Nürnberg 35
Brussels 34
Mountain View 32
Los Angeles 31
Hangzhou 29
Phoenix 29
Tokyo 27
Lachine 26
Paris 26
Kunming 25
Chengdu 24
San Diego 24
Raritan 20
Florence 19
Lappeenranta 18
Philadelphia 18
Jinan 17
Ottawa 17
Hebei 15
Taipei 15
Chennai 14
Dallas 14
Duncan 14
Nanchang 14
Wuhan 13
Bologna 12
Changsha 12
Des Moines 12
London 12
Mumbai 12
Rotterdam 12
San Jose 12
Hong Kong 11
Shenyang 11
Central District 10
Fuzhou 10
Hyderabad 10
Marseille 10
Padova 10
Piemonte 10
Seoul 10
Amsterdam 9
Chicago 9
Den Haag 9
Frankfurt am Main 9
Leawood 9
Mexico 9
Palermo 9
Rochester 9
Zhengzhou 9
Bogotá 8
Budapest 8
Totale 13.564
Salva come PNG Salva come JPEG
Nome #
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients 461
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 427
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 350
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 324
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 292
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 286
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 277
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 256
Chicago 2014 - 30 years of γδ T cells 244
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 204
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 202
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile 182
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 180
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 179
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 176
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 163
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 162
null 148
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 147
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 145
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 141
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 137
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 136
Amplification of T cell activation induced by CD73 (ecto-5' nucleotidase) engagement. 133
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 133
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 133
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 133
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 132
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 132
Effective anti-tumor immunomodulatory properties of zoledronic acid 127
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 125
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 123
CD157 reduces acutemyeloid leukemia cell sensitivity tocytarabine through upregulation of MCL-1 anti-apoptotic protein 121
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 120
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 117
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 117
CD157 REGULATES THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO CHEMOTHERAPY BY MODULATING THE APOPTOTIC RESPONSE 116
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 115
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 115
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 113
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 113
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 113
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 112
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. 112
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells 111
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 111
The tryptophan metabolism in the immune dysregulation of multiple myeloma 111
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 110
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 110
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 110
Anticancer innovative therapy: Highlights from the ninth annual meeting 110
Is there a role for allografting in myeloma ?: an update of a comparative study 109
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 109
Refractory cytopenia with multilinear dysplasia (RCMD) in patient with Fanconi anaemia 108
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 108
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 107
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 106
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 105
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 105
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 104
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 104
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 103
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 103
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 102
A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility 102
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 100
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: Diagnostic challenges and therapeutic options: Two case reports 99
Difference in polyamine transport in human B and T lymphocytes. 98
[Idiotypic study of human myeloma] 98
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 98
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 97
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 97
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 96
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 96
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells 95
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 95
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 95
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 94
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 93
Cytobiological studies in multiple myeloma. 92
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. 92
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 92
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 92
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 92
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. 92
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 91
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 91
B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. 90
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. 89
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 89
Distribution of T-cell signalling molecules in human myeloma 89
CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. 88
Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions 88
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 88
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. 88
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 88
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. 88
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter. 87
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma 87
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma 87
Totale 13.253
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.757
article - articoli 0
book - libri 0
conference - conferenze 26.391
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.148
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.806 0 0 0 0 0 461 360 152 221 252 207 153
2020/20212.693 271 155 170 156 291 125 175 134 321 209 377 309
2021/20223.011 108 89 91 218 123 57 463 159 104 326 648 625
2022/20233.960 415 321 93 347 353 997 312 255 415 132 204 116
2023/20241.918 225 363 120 101 110 344 53 104 15 104 132 247
2024/20252.524 37 294 199 501 1.269 224 0 0 0 0 0 0
Totale 23.430